Gapping up
In reaction to strong earnings/guidance:
- FBP +11.7%, ARCH +7.6%, HOG +7.4%, SNV +5.7%, CDNS +4.6%, PG +4.2%, AMTD +3.6%, PII +2.8%, VBTX +2.7%, UTX +2.3%, CE +2.2%, WSFS +2.2%, EDU +2.1%, PHM +2.1%, BXS +1.4%, ZION +0.9%, UBS +0.9%
Other news:
- BIIB +40.4% (plans to pursue regulatory approval for aducanumab for early Alzheimer's disease -- Company plans to submit Biologics License Application in early 2020; also released earnings)
- STMP +23.5% (Stamps.com and UPS to collaborate on shipping solutions to E-commerce sellers; UPS also announces multiple tech-enabled services, new customers and partners)
- ETON +21.4% (receives FDA approval for Biorphen)
- GNC +16.8% (Harbin Pharmaceutical said to mull bid to take GNC private, according to Bloomberg)
- FBP +11.7% (First Bancorp acquires Banco Santander Puerto Rico in transaction with $425 mln base purchase price)
- BMY +4.4% (says CheckMate -9LA met its primary endpoint of superior overall survival)
- VCYT +2.9% (announces data demonstrating "clinical validity" of Percepta classifier in lung cancer diagnosis)
- SNAP +2.3% (continued strength ahead of earnings tomorrow)
- VRTX +2.1% (FDA has approved TRIKAFTA in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene)
- UAA +2% (appoints COO Patrik Frisk as CEO effective Jan. 1, 2020; Plank will become Executive Chairman & Brand Chief)
- ZEAL +1% (acquires Encycle Therapeutics)
Analyst comments:
- ACRS +6.4% (upgraded to Outperform from Mkt Perform at SVB Leerink)
- PLAN +4.8% (upgraded to Outperform from In-line at Evercore ISI)
- DBX +3.6% (upgraded to Buy from Neutral at Nomura)
- WDAY +2.5% (upgraded to Outperform from In-line at Evercore ISI)
- JNPR +2.1% (upgraded to Neutral from Underweight at JP Morgan)